Cyclopharm (ASX:CYC) secured an agreement with the University of Pennsylvania Health System (UPHS) for its Technegas technology, covering 11 clinical locations across Pennsylvania and New Jersey for an initial three-year term, according to a Monday filing with the Australian bourse.
The agreement provides for two Technegas installations at the Hospital of the University of Pennsylvania and at the Perelman Center for Advanced Medicine, as well as contracted installations across a further nine sites in the UPHS network over time, the filing said.
The agreement also allows for the potential of expanding beyond the initially contracted 11 locations to additional sites affiliated with UPHS, per the filing.